High-dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophy.

Abstract

We describe a patient with cerebellar ataxia of degenerative nature who was administered high-dose piracetam in a single-blind trial. Piracetam was demonstrated to be highly effective on tandem gait and gait ataxia in daily doses of 60 g. We suggest piracetam has a potential anti-ataxic effect in human cerebellar ataxia when used in considerably higher doses than those indicated for other purposes.

• Authors: Melih Vural, Sibel Ozekmekçi, Hülya Apaydin, Attila Altinel
• Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 18 Issue 4 Pg. 457-9 (Apr 2003) ISSN: 0885-3185 [Print] United States
• PMID: 12671958 (Publication Type: Case Reports, Clinical Trial, Journal Article)
• Copyright: Copyright 2002 Movement Disorder Society

Chemical References

• Neuroprotective Agents
• Piracetam

Topics

• Adult
• Atrophy
• Cerebellar Ataxia (diagnosis, drug therapy)
• Cerebellar Cortex (pathology)
• Dose-Response Relationship, Drug
• Female
• Humans
• Magnetic Resonance Imaging
• Neurologic Examination (drug effects)
• Neuroprotective Agents (administration & dosage, adverse effects)
• Piracetam (administration & dosage, adverse effects)
• Single-Blind Method
• Spinocerebellar Degenerations (diagnosis, drug therapy)
• Treatment Outcome
• Walking